Gilead Sciences, Inc.
GILD · Healthcare · Biotechnology
Updated 27 min ago · data delayed ≥15 min
IconicScore
ProprietaryRanked #63 of 500 by Iconic Score · #8 of 59in its sector. IconicAlpha’s proprietary brand-intelligence metric — a multi-model blend of scale, market attention, category leadership, and AI-analyzed brand visibility.
Get the free morning email
The biggest IconicScore™ gainer and loser, plus the strongest and weakest sectors, in your inbox before the open. See a sample →
Price performance
Export history · AnalystThis insight is part of the Analyst tier — unlock the IconicScore vs. price overlay, side-by-side comparison, and CSV export.
Upgrade to AnalystThis is part of the Enterprise tier — benchmark your IconicScore against sector peers, claim your profile, and manage how your brand appears on the wall.
Upgrade to EnterpriseIconic Profile
Gilead Sciences, Inc. (GILD) is a leading biotechnology company focused on the discovery, development, and commercialization of innovative therapeutics in areas of unmet medical need, particularly in antiviral treatments for HIV, hepatitis B, hepatitis C, and influenza, as well as oncology and inflammatory diseases. With a market capitalization of $161.8 billion, Gilead holds a strong position in the healthcare sector, driven by its robust pipeline and established portfolio of antiviral therapies. The company's commitment to advancing science and improving patient outcomes makes it a significant player in the biotechnology landscape, contributing to public health advancements and addressing critical healthcare challenges globally. Gilead's strategic focus on research and development, along with its collaborations and partnerships, further enhances its ability to deliver impactful solutions in the evolving healthcare market.
IconicOracleAI™ Brief
Gilead Sciences, Inc. currently holds an Iconic Score of 61, reflecting a stable brand presence amid mixed market sentiment. The company's recent FDA drug approvals have garnered attention, contributing to a brand-visibility signal of 85/100 from logo analysis. Despite a slight decline in stock price, Gilead's market cap remains robust at $192.2 billion, indicating sustained investor interest in its pharmaceutical innovations.
AI-generated explanation of current score drivers. Not investment advice.
Enterprise tier: claim your logo to manage how your brand is represented.